

Title

COVID-19: Public Compliance with and Public Support for Stay-at-Home Mitigation Strategies

Authors

Mark É. Czeisler, A.B.,^{1,2} Mark E. Howard, MBBS, Ph.D.,^{1,2,3} Rebecca Robbins, Ph.D.,^{4,5} Laura K. Barger, Ph.D.,^{4,5} Elise R. Facer-Childs, Ph.D.,¹ Shantha M. W. Rajaratnam, Ph.D.,^{1,4,5} ¶ Charles A. Czeisler, Ph.D., M.D.^{4,5} ¶

¹School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria 3800 Australia

²Institute for Breathing and Sleep, Austin Health, Melbourne, Victoria 3084 Australia

³Department of Medicine, University of Melbourne, Melbourne, Victoria 3010 Australia

⁴Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, Massachusetts 02115 USA

⁵Division of Sleep Medicine, Harvard Medical School, Boston, MA 02115 USA

¶ Dr. Rajaratnam and Dr. Czeisler contributed equally to this manuscript.

ORCIDs: M.É.C. (0000-0003-3100-7347), M.E.H. (0000-0001-7772-1496), R.R. (0000-0003-0288-2505), L.K.B. (0000-0001-8547-7331), E.R.F-C. (0000-0003-4549-9266), S.M.W.R. (0000-0001-7527-8558), C.A.C. (0000-0002-7408-1849)

Corresponding Author: Charles A. Czeisler, PhD, MD, Departments of Medicine and Neurology, Brigham & Women's Hospital, 221 Longwood Ave, Suite 438A, Boston, MA USA 02115-5817; Telephone: 617-571-5797; E-mail address: czeisler@g.harvard.edu

ABSTRACT

Objectives

Governments worldwide have recommended unprecedented measures to mitigate the coronavirus disease 2019 (COVID-19) pandemic. As pressure mounts to scale back these measures, understanding public compliance with and priorities for COVID-19 mitigation is critical. The main aim of this study was to assess public compliance with and support for government-imposed stay-at-home orders in nations and cities with different COVID-19 infection and death rates.

Design

In this cross-sectional study, questionnaires were administered to nationally representative respondents from April 2-8, 2020.

Setting

Regions with different disease prevalence included two nations [the United States (US—high) and Australia (AU—low)] and two cities [New York (NY—high) and Los Angeles (LA—low)].

Participants

For adults 18 years or older residing in specified regions, eligible respondents were empaneled until representative quotas were reached for age, gender, and either race and ethnicity (US, NY, LA) or ancestry (AU), matching the 2010 US or 2016 AU census. Of 8718 eligible potential respondents, 5573 (response rate, 63.9%) completed surveys (US: 3010; NY: 507; LA: 525; AU: 1531). The median age was 47 years (range, 18-89); 3039 (54.5%) were female.

Exposure

The prevalence of COVID-19 in each region (cumulative infections, deaths) as of April 8, 2020: US (458610, 15659), AU (5956, 45),¹ NY (81803, 4571), LA (7530, 198).²

Main Outcomes Measures

Public compliance with and attitudes regarding government-imposed stay-at-home orders were evaluated and compared between regions.

Results

Of 5573 total respondents, 4560 (81.8%) reported compliance with recommended quarantine or stay-at-home policies (range of samples, 75.5%-88.2%). Despite significant disruptions of social and work life, health, and behavior, 5022 respondents (90.1%) supported government-imposed stay-at-home orders (range of samples, 88.9%-93.1%). Of these, 90.8% believe orders should last at least three more weeks or until public health or government officials recommend, with such support spanning the political spectrum.

Conclusions

Public compliance with stringent quarantine and stay-at-home policies was very high, in both highly-affected (US, NY) and minimally-affected regions (AU, LA). Despite extensive disruption of respondents' lives, the vast majority supported continuation of long-term government-imposed stay-at-home orders. These findings have important implications for policymakers grappling with the decision as to when to lift restrictions.

Introduction

To date, more than 2,500,000 confirmed cases and 175,000 deaths have been attributed to the novel coronavirus disease 2019 (COVID-19) pandemic.³ Absent widespread testing or safe and efficacious treatments, isolation and quarantine have been recommended worldwide for the first time in a century. Disease prevalence and associated public health policies have varied across jurisdictions and changed over time, largely without systematic assessment of public responses to the crisis or the mitigation strategies.

Methods

Study Design and Recruitment

To evaluate public compliance with and support for recommended COVID-19 mitigation strategies, we collected cross-sectional surveys of nationally representative respondents using demographic quota sampling.⁴ Surveys were administered to an online respondent panel by Qualtrics, LLC (Provo, Utah, and Seattle, Washington, US), a commercial survey company with a network of participant pools consisting of hundreds of suppliers. Recruitment methodologies include digital advertisements and promotions, word of mouth and membership referrals, social networks, TV and radio advertisements, and offline mail-based approaches.

Between April 2-8 2020 (a one-week period), samples were drawn from regions with markedly different infection and death rates from COVID-19 (Table 1), including nationwide samples in the United States (US, high incidence) and Australia (AU, low incidence), and two citywide samples in the New York (NY, high incidence) and Los

Angeles (LA, low incidence) metropolitan areas.

Study Approval

The study protocol was approved by the Monash University Human Research Ethics Committee (MUHREC) and conducted in accordance with ethical guidelines.

Respondents were informed of the study purposes and provided electronic consent prior to commencement. Investigators received anonymized responses.

Population

Target numbers of respondent-completed surveys follows: US (3000), NY (500), LA (500), AU (1500). To be eligible to participate, respondents were required to report being aged 18 years or older with current residence in specified regions. Demographic sampling quotas were implemented for age, gender, and either race and ethnicity (US, NY, LA) or ancestry (AU), based on 2010 US and 2016 Australian census data.

Potential respondents likely to qualify based on demographic characteristics listed in their Qualtrics panelist profile were targeted during recruitment; demographic questions were included in the survey to confirm eligibility. Potential respondents received invitations and could opt to participate by activating a survey link directing them to the participant information and consent page preceding the survey. Ineligible respondents who did not meet inclusion criteria (e.g., less than 18 years of age, not a resident of a targeted region) or exceeded set quotas (i.e., maximum demographic characteristic quota already met) were disempaneled from the survey.

Survey Instruments

The surveys contained 86 [United States (US), New York (NY), Los Angeles (LA)] or 85

[culturally adapted for Australia (AU)] items, with each item requiring a response, and was designed to take approximately 15 minutes to complete. Respondents were required to self-report demographic characteristics and respond to questions about COVID-19 and mitigation strategies including compliance, priorities, sources of concern, and comparisons of current lifestyle versus lifestyle between October and December 2019 (i.e., before COVID-19 and mitigation strategies). Additional health-related questions were asked independent of COVID-19. When possible, brief validated instruments were used, including the Short-Form Sleep Condition Indicator (SCI-01) for insomnia risk assessment, Patient Health Questionnaire-4 (PHQ-4) for anxiety and depression risk assessment, the Perceived Stress Scale-4 (PSS-4) for perceived stress assessment, and the Mini Z for burnout risk assessment.⁵⁻⁸ When required, validated instruments were adapted, including the Horne and Östberg Morningness-Eveningness Questionnaire (MEQ) for chronotype assessment, the μ short Munich ChronoType Questionnaire (μ MCTQ) for chronotype and sleep behavior assessment, Obstructive Sleep Apnoea 50 (OSA50) for obstructive sleep apnea risk assessment, single-item physical activity measure, and Hurt-Insult-Threaten-Scream (HITS) screening tool for domestic violence.⁹⁻¹⁴

Quality Screening

To verify response quality, Qualtrics conducted standardized quality screening and data scrubbing procedures. Techniques included algorithmic analysis for attention patterns, click-through behavior, duplicate responses, keystroke analysis, machine responses, and inattentiveness. Country-specific geolocation verification via IP address mapping was used to ensure respondents were from the country specified in their response.

Respondents who failed an attention or speed check, along with any responses identified by the data scrubbing algorithms, were excluded from the final sample.

Results

Between April 2 and April 8, 2020, respondents completed 5573 surveys (US: 3010; NY: 507; LA: 525; AU: 1531) with a 63.9% response rate (Figure 1). Overall, 3039 (54.5%) were female; the median age of participants was 47 years (range, 18-89). See Table 2 for respondent characteristics. Cross-sectional results of COVID-19-mitigation compliance, public priorities, and life impact for each sample are reported by region (Figure 2; Table 1). Altogether, 4560 respondents (81.8%) reported quarantining or voluntarily self-isolating (range of samples, 75.5%-88.2%). Moreover, 5022 (90.1%) believe a government-imposed stay-at-home order is warranted (range of samples, 88.9%-93.1%). Of these, 90.8% believe the order should last at least three more weeks (9.1%), a month or longer (43.8%), or until public health (31.1%) or government officials (6.8%) determine it is safe to lift the restrictions. Of 5304 respondents (95.2%) who made predictions, the average predicted date by which COVID-19 would no longer affect their daily lives was between mid-June and mid-August, though there was high variability in predictions. Strong support for a government-imposed stay-at-home order spanned the political spectrum (Table 1).

Overall, 4431 respondents (79.5%, range of samples, 77.5%-82.1%) reported moderate to extreme concern about their own (61.9%) or others' (75.5%) infection and 3974 (71.3%, range of samples, 69.8%-76.0%) about their own (43.4%) or others' (68.7%) death. Access to testing (59.3%), medical care for COVID-19 (64.5%), medical care for pre-existing conditions due to hospital overload (59.2%), social or physical isolation

(58.1%), and sense of purpose (49.8%) were also sources of moderate to extreme concern. Overall, 1217 respondents (21.8%) identified as high risk for severe COVID-19 infection. Across regions, nearly half (42.0%-45.3%) reported spending considerable time (average, 23.2 hours per week) consuming information (media, government reports, health officials, family) about COVID-19. NY had the highest percentage of respondents who reported knowing someone who has tested positive for (27.0% vs. 5.6%-11.0%), been hospitalized for (14.6% vs. 2.4%-6.5%) or died from (9.5% vs. 0.7%-2.9%) COVID-19.

Consistent across regions, respondents reported that COVID-19 and mitigation strategies have caused moderate to extreme disruption of social life (75.3%), family life (41.0%), work/studies (43.5%), productivity (41.6%), physical activity (45.1%), sexual activity (23.6%), and sleep patterns (39.3%). Overall, 1999 respondents (35.9%) reported exercising less frequently, and 409 (7.4%) reported concerning weight gain. Daily outdoor light exposure was reduced by 1 hour or more in 2279 respondents (40.9%). The estimated percentage of virtual interactions (versus face-to-face) increased from 14.6% to 66.1%, and 1786 respondents (32.0%) reported more than 1 hour increase in daily screen time.

Widespread concerns included the possibility of an economic recession and open-endedness of COVID-19 and mitigation measures (79.2% and 72.2%, respectively). A total of 3119 respondents (56.0%) reported feeling anxious or nervous, 2453 (44.0%) depressed or hopeless, and 2511 (45.1%) unable to stop or control worrying at least several days in the prior two weeks.

Discussion

Resounding compliance with and support for disruptive mitigation measures evidenced in these nationally representative samples, despite belief by 91.4% of respondents that they will never be infected with COVID-19 (range of samples, 89.2%-92.6%), suggests that controlling COVID-19 is a top public priority.¹⁵ We used quota sample surveys to rapidly assess public compliance, priorities, and life impact related to COVID-19 and mitigation strategies. We recognize the potential for self-selection bias; however, the high response rate (63.9%) and consistency of responses across cities and countries despite different rates of infection, governments, and mitigation strategies indicate that these results are robust. Contrary to public attitudes and compliance with recommended mitigation during the last pandemic¹⁶⁻¹⁷ declared by the World Health Organization for novel influenza A (H1N1) in 2009,¹⁸ the public response to the COVID-19 pandemic represents a hitherto unprecedented and rapid level of compliance with public health emergency measures that have and will continue to have a profound impact on economics and public life. These results demonstrate an escalated public response compared to before shelter-in-place orders were widely implemented,¹⁹ and contribute to a growing body of evidence that mitigation strategies for COVID-19, like those for previous outbreaks, are associated with significant disruption of life and general health consequences.²⁰⁻²⁵ These findings may also provide insight into behavioral countermeasures related to sleep, exercise, and diet that may reduce adverse health consequences of COVID-19 mitigation measures. As controversies over the legality²⁶ and balance between duration and nature of mitigation strategies and related consequences continue to mount, and with the recent prospect of repeated and

protracted stay-at-home orders being recommended over the next two years,²⁷
assessment of public priorities, compliance, and life impact is paramount.

Compliance with and support for COVID-19 mitigation strategies, alongside concerns and life impact, were assessed in nationally representative samples in the United States and Australia. These timely findings indicate that the public is not only willing to accept current mitigation measures and their associated costs, but that people endorse their continuation until the COVID-19 pandemic is controlled.

ACKNOWLEDGEMENTS

Author Contributions

M.É.C. had full access to all data in the study and takes responsibility for the integrity of the data and accuracy of data analyses.

Concept and design: All authors.

Acquisition and analysis of data: M.É.C.

Drafting of the manuscript: M.É.C., S.M.W.R., C.A.C.

Critical revision of the manuscript for important intellectual content: All authors.

Supervision: M.E.H., S.M.W.R., C.A.C.

Funders

This study was supported in part by the Institute for Breathing and Sleep, Austin Health; the Turner Institute for Brain and Mental Health, Monash University; and by a gift to the Harvard Medical School from Philips Respironics. M.É.C. was supported by a 2020 Fulbright Future Scholarship funded by the Kinghorn Foundation through the Australian-American Fulbright Commission. L.K.B. and C.A.C. were supported in part by the National Institute of Occupational Safety and Health R01-OH-010300. C.A.C. serves as the incumbent of an endowed professorship provided to Harvard Medical School by Cephalon, Inc. The funders were not involved in the design and conduct of the study, the collection, preparation, or interpretation of the data, or the preparation or approval of the manuscript.

Conflict of Interest Disclosures

C.A.C. reports grants from Cephalon Inc., Jazz Pharmaceuticals Plc., Inc., Philips Respironics, Inc., Regeneron Pharmaceuticals, ResMed Foundation, San Francisco Bar Pilots, Sanofi S.A., Sanofi-Aventis, Inc, Schneider Inc., Sepracor, Inc, Mary Ann & Stanley Snider via Combined Jewish Philanthropies, Teva Pharmaceuticals Industries, Ltd.; and personal fees from Bose Corporation, Columbia River Bar Pilots, Ganésco Inc., Institute of Digital Media and Child Development, Klarman Family Foundation, Samsung Electronics, Quest Diagnostics, Inc., Teva Pharma Australia, Vanda Pharmaceuticals, Washington State Board of Pilotage Commissioners, Zurich Insurance Company, Ltd. In addition, C.A.C. holds a number of process patents in the field of sleep/circadian rhythms (e.g., photic resetting of the human circadian pacemaker) and holds an equity interest in Vanda Pharmaceuticals, Inc. Since 1985, C.A.C. has also served as an expert on various legal and technical cases related to sleep and/or circadian rhythms, including those involving the following commercial entities: Casper Sleep Inc., Comair/Delta Airlines, Complete General Construction Company, FedEx, Greyhound, HG Energy LLC, Purdue Pharma, LP, Steel Warehouse Inc., Stric-Lan Companies LLC, Texas Premier Resource LLC, and United Parcel Service (UPS). CAC receives royalties from Philips Respironics, Inc. for the Actiwatch-2 and Actiwatch-Spectrum devices. Interests for C.A.C. were reviewed and managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies.

Additional Contributions

We thank Qualtrics, LLC for their support of survey administration and data collection.

REFERENCES

1. Coronavirus disease 2019 (COVID-19) Situation Report – 76. World Health Organization. [Cited 2020 April 10]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200405-sitrep-76-covid-19.pdf?sfvrsn=6ecf0977_4.
2. Coronavirus (Covid-19) Data in the United States; 2020 [cited 2020 April 10]. Database: The New York Times [Internet]. Available from: <https://github.com/nytimes/covid-19-data>.
3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*; published online Feb 19. doi: 10.1016/S1473-3099(20)30120-1.
4. Miller CA, Guidry JPD, Dahman B, Thomson MD. A Tale of Two Diverse Qualtrics Samples: Information for Online Survey Researchers. *Cancer Epidemiol Biomarkers Prev*. 2020;29(4):731–735. doi: 10.1158/1055-9965.EPI-19-0846.
5. Espie CA, Kyle SD, Hames P, Gardani M, Fleming L, Cape J. The Sleep Condition Indicator: a clinical screening tool to evaluate insomnia disorder. *BMJ Open*. doi: 10.1136/bmjopen-2013-004183.
6. Löwe B, Wahl I, Rose M, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. *J Affect Disord*. 2010;122(1-2):86-95. doi: 10.1016/j.jad.2009.06.019.
7. Lee E-H. Review of the Psychometric Evidence of the Perceived Stress Scale. *Asian Nurs Res*. 2012;6(4):121-7. doi: 10.1016/j.anr.2012.08.004.
8. Dolan ED, Mohr D, Lempa M, et al. Using a Single Item to Measure Burnout in Primary Care Staff: A Psychometric Evaluation. *J Gen Intern Med*. 2015;30(5):582-7. doi: 10.1007/s11606-014-3112-6.
9. Horne JA, Östberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. *Int J Chronobiol*. 1976;4(2):97-110.

10. Ghotbi N, Pilz LK, Winnebeck EC, et al. The μ MCTQ: An Ultra-Short Version of the Munich ChronoType Questionnaire. *J Biol Rhythms*. 2020;35(1):98-110. doi: 10.1177/0748730419886986.
11. Chai-Coetzer CL, Antic NA, Rowland LS, et al. A simplified model of screening questionnaire and home monitoring for obstructive sleep apnoea in primary care. *Thorax*. 2011;66(3):213-9. doi: 10.1136/thx.2010.152801.
12. Milton K, Bull FC, Bauman A. Reliability and validity testing of a single-item physical activity measure. *Br J Sports Med*. 2011;45(3):203-8. doi: 10.1136/bjism.2009.068395.
13. Sherin KM, Sinacore JM, Li XQ, Zitter RE, Sahkil A. HITS: a short domestic violence screening tool for use in a family practice setting. *Fam Med*. 1998;30(7):508-12.
14. Shakil A, Donald S, Sinacore JM, Krepcho M. Validation of the HITS domestic violence screening tool with males. *Fam Med*. 2005;37(3):193-8.
15. Zhang X, Wang F, Zhu C, Wang Z. Willingness to Self-Isolate when Facing a Pandemic Risk: Model, Empirical Test, and Policy Recommendations. *Int J Environ Res Public Health*. 2019;17(1):197. Published online December 27, 2019. doi: 10.3390/ijerph17010197.
16. Jhummon-Mahadnac ND, Knott J, Marshall C. A cross-sectional study of pandemic influenza health literacy and the effect of a public health campaign. *BMC Res Notes*. 2012;5(377). doi: 10.1186/1756-0500-5-377.
17. Kavanagh AM, Bentley RJ, Mason KE, et al. Sources, perceived usefulness and understanding of information disseminated to families who entered home quarantine during the H1N1 pandemic in Victoria, Australia: a cross-sectional study. *BMC Infect Dis*. 2011;11(2). doi: 10.1186/1471-2334-11-2.
18. World now at the start of 2009 influenza pandemic. World Health Organization. [Cited 2020 April 13]. Available from: https://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/.

19. Nelson LM, Simard JF, Oluyomi A, et al. US Public Concerns About the COVID-19 Pandemic From Results of a Survey Given via Social Media. *JAMA Intern Med*. Published online April 07, 2020. doi: 10.1001/jamainternmed.2020.1369.
20. Hawryluck L, Gold WL, Robinson S, Pogorski S, Galea S, Styra R. SARS control and psychological effects of quarantine, Toronto, Canada. *Emerg Infect Dis*. 2004;10:1206-12. doi: 10.3201/eid1007.030703.
21. Van Bortel T, Basnayake A, Wurie F, Jambai M, Koroma AS, Muana AT, et al. Psychosocial effects of an Ebola outbreak at individual, community and international levels. *Bull World Health Organ*. 2016;94:210–4. doi: <http://dx.doi.org/10.2471/BLT.15.158543>.
22. Lai J, Ma S, Wang Y, et al. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. *JAMA Netw Open*. 2020;3(3):e203976. doi: 10.1001/jamanetworkopen.2020.3976.
23. Wang C, Pan R, Wan X, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. *Int J Environ Res Public Health*. 2020;17(5). pii: E1729. doi: 10.3390/ijerph17051729.
24. Li S, Wang Y, Xue J, Zhao N, Zhu T. The Impact of COVID-19 Epidemic Declaration on Psychological Consequences: A Study on Active Weibo Users. *Int J Environ Res Public Health*. 2020;17(6):2032. doi: 10.3390/ijerph17062032.
25. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet*. 2020;395(10227):912–920. doi: 10.1016/S0140-6736(20)30460-8.
26. Parmet WE, Sinha MS. Covid-19 - The Law and Limits of Quarantine. *N Engl J Med*. 2020;382(15):e28. doi: 10.1056/NEJMp2004211.
27. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science*. Published online April

14, 2020. doi: 10.1126/science.abb5793.

28. Coronavirus disease 2019 (COVID-19) Situation Report – 73. World Health Organization.

[Cited 2020 April 10]. Available from: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_6)

[source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_6](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_6).

29. Coronavirus disease 2019 (COVID-19) Situation Report – 79. World Health Organization.

[Cited 2020 April 10]. Available from: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200408-sitrep-79-covid-19.pdf?sfvrsn=4796b143_6)

[source/coronaviruse/situation-reports/20200408-sitrep-79-covid-19.pdf?sfvrsn=4796b143_6](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200408-sitrep-79-covid-19.pdf?sfvrsn=4796b143_6).

Figure 1. Flow of Survey Respondents





Fig 1. The survey was managed through an online respondent panel by Qualtrics. A *priori* quota limits were determined prior to study initiation to ensure nationally representative samples were collected and included the following: age, gender, and either race and ethnicity (US, NY, LA) or ancestry (AU), based on 2010 US and 2016 Australian census data. Of 8718 eligible potential respondents, 5573 completed surveys, providing a 63.9% response rate.

Figure 2. Public COVID-19 Mitigation Compliance, Concerns, Policy Support and Experience

A. Compliance, Concerns and Policy Support



B. Behavioral Changes




Fig 2. (A) Percentage of respondents by region who report: compliance with nationally recommended mitigation strategies; support for a government-mandated stay-at-home order; perceived risk of eventual infection with COVID-19; personal experience with COVID-19 (i.e., knowing someone who was infected with or died from COVID-19); and moderate to extreme concerns regarding: one's own or others' risk of infection with or death from COVID-19, personal financial loss, and possible economic recession. (B) Upper quadrants: Impact by region of COVID-19 and mitigation strategies on social life, family life, work and/or study, productivity, sleep patterns, physical activity, and sexual activity; percentage of respondents reporting that the indicated behavioral category was moderately to extremely disrupted or improved is shown. Lower quadrants: Percentage of respondents reporting decreases or increases in six categories [virtual interactions vs. face-to-face interactions; time spent outdoors during daylight hours; time on light-emitting screens; weekly work hours (among respondents employed in the fourth quarter of 2019, n=3328); commute time; and weight] at the time of the survey in April, 2020 (after the COVID-19 pandemic was declared and mitigation was underway) as compared to the fourth quarter of 2019 (before the COVID-19 pandemic was declared).

Table 1. Summary of Results Overall and by Region

	Overall (N=5573)	US (N=3010)	NY (N=507)	LA (N=525)	AU (N=1531)
Regional infections and deaths due to COVID-19					
Cumulative regional confirmed cases					
Study midpoint (April 5 2020)	352935	273808	67552	5940	5635
Range (April 2—April 8, 2020)	248133—458610	187302—363321	51810—81803	4045—7530	4976—5956
Cumulative regional deaths					
Study midpoint (April 5 2020)	9658	7020	2472	132	34
Range (April 2—April 8, 2020)	5507—15659	3846—10845	1562—4571	78—198	21—45
Compliance with COVID-19 Mitigation Strategies					
Social/Physical Distance—No. (%)					
Not in quarantine or self-isolation	1013 (18.2)	508 (16.9)	68 (13.4)	62 (11.8)	375 (24.5)
In quarantine or self-isolation	4560 (81.8)	2502 (83.1)	439 (86.6)	463 (88.2)	1156 (75.5)
Quarantine ^a	1946 (34.9) (42.7)	1151 (38.2) (46.0)	214 (42.2) (48.7)	224 (42.7) (48.4)	357 (23.3) (30.9)
Self-isolation	2614 (46.9) (57.3)	1351 (44.9) (54.0)	225 (44.4) (51.3)	239 (45.5) (51.6)	799 (52.2) (69.1)
Predictions for When COVID-19 Will Stop Affecting Daily Life					
Respondents offering predictions ^a —No. (%)	5304 (95.2)	2878 (95.6)	480 (94.7)	501 (95.4)	1445 (94.4)
Number of days from survey completion date—mean, sd	92.5 99.4	76.4 84.1	79.4 77.0	78.6 77.5	134.0 125.5
Calendar Date	7/5/2020	6/16/2020	6/22/2020	6/21/2020	8/15/2020
Public Priorities for COVID-19 Mitigation Strategies					
Government should impose stay-at-home order ^c —No. (%)					
No	551 (9.9)	300 (10.0)	45 (8.9)	36 (6.9)	170 (11.1)
Yes	5022 (90.1)	2710 (90.0)	462 (91.1)	489 (93.1)	1361 (88.9)
for one week	89 (1.6) (1.8)	56 (1.9) (2.1)	6 (1.2) (1.3)	8 (1.5) (1.6)	19 (1.2) (1.4)
for two weeks	373 (6.7) (7.4)	215 (7.1) (7.9)	46 (9.1) (10.0)	25 (4.8) (5.1)	87 (5.7) (6.4)
for three weeks	457 (8.2) (9.1)	271 (9.0) (10.0)	51 (10.1) (11.0)	49 (9.3) (10.0)	86 (5.6) (6.3)
for at least one month	2201 (39.5) (43.8)	1298 (43.1) (47.9)	190 (37.5) (41.1)	254 (48.4) (51.9)	459 (30.0) (33.7)
until health officials say it is safe	1562 (28.0) (31.1)	737 (24.5) (27.2)	133 (26.2) (28.8)	127 (24.2) (26.0)	565 (36.9) (41.5)
until government officials say it is safe	340 (6.1) (6.8)	133 (4.4) (4.9)	36 (7.1) (7.8)	26 (5.0) (5.3)	145 (9.5) (10.7)
By political affiliation					
Very liberal	701 (12.6)	410 (13.6)	97 (19.1)	94 (17.9)	100 (6.5)
No	51 (0.9) (7.3)	30 (1.0) (7.3)	4 (0.8) (4.1)	2 (0.4) (2.1)	15 (1.0) (15.0)
Yes	650 (11.7) (92.7)	380 (12.6) (92.7)	93 (18.3) (95.9)	92 (17.5) (97.9)	85 (5.6) (85.0)
Somewhat liberal	1121 (20.1)	586 (19.5)	107 (21.1)	129 (24.6)	299 (19.5)
No	64 (1.1) (5.7)	28 (0.9) (4.8)	4 (0.8) (3.7)	6 (1.1) (4.7)	26 (1.7) (8.7)
Yes	1057 (19.0) (94.3)	558 (18.5) (95.2)	103 (20.3) (96.3)	123 (23.4) (95.3)	273 (17.8) (91.3)
Neither liberal nor conservative	1465 (26.3)	727 (24.2)	122 (24.1)	126 (24.0)	490 (32.0)
No	161 (2.9) (11.0)	81 (2.7) (11.1)	9 (1.8) (7.4)	9 (1.7) (7.1)	62 (4.0) (12.7)
Yes	1304 (23.4) (89.0)	646 (21.5) (88.9)	113 (22.3) (92.6)	117 (22.3) (92.9)	428 (28.0) (87.3)
Somewhat conservative	1097 (19.7)	621 (20.6)	80 (15.8)	84 (16.0)	312 (20.4)
No	117 (2.1) (10.7)	59 (2.0) (9.5)	12 (2.4) (15.0)	12 (2.3) (14.3)	34 (2.2) (10.9)
Yes	980 (17.6) (89.3)	562 (18.7) (90.5)	68 (13.4) (85.0)	72 (13.7) (85.7)	278 (18.2) (89.1)
Very conservative	701 (12.6)	484 (16.1)	60 (11.8)	58 (11.0)	99 (6.5)
No	97 (1.7) (13.8)	70 (2.3) (14.5)	11 (2.2) (18.3)	6 (1.1) (10.3)	10 (0.7) (10.1)
Yes	604 (10.8) (86.2)	414 (13.8) (85.5)	49 (9.7) (81.7)	52 (9.9) (89.7)	89 (5.8) (89.9)
Apolitical/prefer not to say	488 (8.8)	182 (6.0)	41 (8.1)	34 (6.5)	231 (15.1)
No	61 (1.1) (12.5)	32 (1.1) (17.6)	5 (1.0) (12.2)	1 (0.2) (2.9)	23 (1.5) (10.0)
Yes	427 (7.7) (87.5)	150 (5.0) (82.4)	36 (7.1) (87.8)	33 (6.3) (97.1)	208 (13.6) (90.0)
Experience with COVID-19					
Believe to have been exposed to COVID-19 in the past two weeks—No. (%)					
No	5302 (95.1)	2854 (94.8)	463 (91.3)	496 (94.5)	1489 (97.3)
Yes	271 (4.9)	156 (5.2)	44 (8.7)	29 (5.5)	42 (2.7)
Tested for COVID-19—No. (%)					
No	5454 (97.9)	2954 (98.1)	489 (96.4)	514 (97.9)	1497 (97.8)
Yes	119 (2.1)	56 (1.9)	18 (3.6)	11 (2.1)	34 (2.2)
Positive	10 (0.2) (8.4)	5 (0.2) (8.9)	4 (0.8) (22.2)	0 (0.0) (0.0)	1 (0.1) (2.9)
Negative	88 (1.6) (73.9)	36 (1.2) (64.3)	13 (2.6) (72.2)	11 (2.1) (100.0)	28 (1.8) (82.4)
Awaiting results	21 (0.4) (17.6)	15 (0.5) (26.8)	1 (0.2) (5.6)	0 (0.0) (0.0)	5 (0.3) (14.7)
Hospitalized for COVID-19—No. (%)					
No	5535 (99.3)	2990 (99.3)	500 (98.6)	519 (98.9)	1526 (99.7)
Yes	38 (0.7)	20 (0.7)	7 (1.4)	6 (1.1)	5 (0.3)
^a Quarantine was defined as "not attending public places, including work, supermarkets or pharmacies, school or childcare, places of worship, etc. Individuals in quarantine do not have visitors and only live with people who usually live in your home. They stay at home or accommodation unless medical care is required."					
^b Predictions in the year 2030 or beyond were excluded. There were six such predictions, which follow: (US, 8/6/2064, 2/1/2071), (LA, 1/1/2030, 1/1/2032, 12/31/2050), (AU, 8/10/2066)					
^c Stay-at-home was defined as "all non-essential services, such as dine-in restaurants, bars, social venues, gyms, fitness studios, and convention centers, are shut down. Essential services, such as groceries, pharmacies, gas stations, food banks, convenience stores, and delivery restaurants, remain open. Banks, local governments that provide services, and law enforcement agencies also remain open."					

	Overall (N=5573)	US (N=3010)	NY (N=507)	LA (N=525)	AU (N=1531)
Experience with COVID-19					
Know someone who has...					
Tested positive for COVID-19—No. (%)					
No	4971 (89.2)	2679 (89.0)	370 (73.0)	476 (90.7)	1446 (94.4)
Yes	602 (10.8)	331 (11.0)	137 (27.0)	49 (9.3)	85 (5.6)
Colleague(s)	141 (2.5) (23.4)	74 (2.5) (22.4)	40 (7.9) (29.2)	4 (0.8) (8.2)	23 (1.5) (27.1)
Family Member(s)	120 (2.2) (19.9)	71 (2.4) (21.5)	30 (5.9) (21.9)	7 (1.3) (14.3)	12 (0.8) (14.1)
Friend(s)	315 (5.7) (52.3)	165 (5.5) (49.8)	83 (16.4) (60.6)	30 (5.7) (61.2)	37 (2.4) (43.5)
Significant other(s)	28 (0.5) (4.7)	18 (0.6) (5.4)	4 (0.8) (2.9)	0 (0.0) (0.0)	6 (0.4) (7.1)
Other	75 (1.3) (12.5)	42 (1.4) (12.7)	11 (2.2) (8.0)	9 (1.7) (18.4)	13 (0.8) (15.3)
Been hospitalized due to COVID-19					
No	5237 (94.0)	2818 (93.6)	433 (85.4)	491 (93.5)	1495 (97.6)
Yes	336 (6.0)	192 (6.4)	74 (14.6)	34 (6.5)	36 (2.4)
Colleague(s)	68 (1.2) (20.2)	39 (1.3) (20.3)	16 (3.2) (21.6)	4 (0.8) (11.8)	9 (0.6) (25.0)
Family Member(s)	80 (1.4) (23.8)	51 (1.7) (26.6)	14 (2.8) (18.9)	7 (1.3) (20.6)	8 (0.5) (22.2)
Friend(s)	168 (3.0) (50.0)	85 (2.8) (44.3)	42 (8.3) (56.8)	20 (3.8) (58.8)	21 (1.4) (58.3)
Significant other(s)	15 (0.3) (4.5)	8 (0.3) (4.2)	3 (0.6) (4.1)	2 (0.4) (5.9)	2 (0.1) (5.6)
Other	42 (0.8) (12.5)	28 (0.9) (14.6)	5 (1.0) (6.8)	6 (1.1) (17.6)	3 (0.2) (8.3)
Died due to COVID-19					
No	5415 (97.2)	2924 (97.1)	459 (90.5)	512 (97.5)	1520 (99.3)
Yes	158 (2.8)	86 (2.9)	48 (9.5)	13 (2.5)	11 (0.7)
Colleague(s)	27 (0.5) (17.1)	13 (0.4) (15.1)	9 (1.8) (18.8)	1 (0.2) (7.7)	4 (0.3) (36.4)
Family Member(s)	15 (0.3) (9.5)	7 (0.2) (8.1)	6 (1.2) (12.5)	1 (0.2) (7.7)	1 (0.1) (9.1)
Friend(s)	81 (1.5) (51.3)	44 (1.5) (51.2)	26 (5.1) (54.2)	6 (1.1) (46.2)	5 (0.3) (45.5)
Significant other(s)	12 (0.2) (7.6)	9 (0.3) (10.5)	1 (0.2) (2.1)	0 (0.0) (0.0)	2 (0.1) (18.2)
Other	39 (0.7) (24.7)	22 (0.7) (25.6)	11 (2.2) (22.9)	5 (1.0) (38.5)	1 (0.1) (9.1)
Concerns Related to COVID-19 and Mitigation Strategies					
Believe eventual infection—No. (%)					
No	5091 (91.4)	2748 (91.3)	452 (89.2)	473 (90.1)	1418 (92.6)
Yes	482 (8.6)	262 (8.7)	55 (10.8)	52 (9.9)	113 (7.4)
Believe high risk for severe illness if infected—No. (%)					
No	4356 (78.2)	2318 (77.0)	404 (79.7)	406 (77.3)	1228 (80.2)
Yes	1217 (21.8)	692 (23.0)	103 (20.3)	119 (22.7)	303 (19.8)
Degree, if any, of concern about the following—No. (%)					
Risk of own infection					
Moderate	1513 (27.1)	831 (27.6)	120 (23.7)	136 (25.9)	426 (27.8)
Strong	917 (16.5)	477 (15.8)	99 (19.5)	94 (17.9)	247 (16.1)
Extreme	1021 (18.3)	563 (18.7)	120 (23.7)	115 (21.9)	223 (14.6)
Risk of others' infection					
Moderate	1447 (26.0)	788 (26.2)	109 (21.5)	115 (21.9)	435 (28.4)
Strong	1344 (24.1)	710 (23.6)	131 (25.8)	135 (25.7)	368 (24.0)
Extreme	1417 (25.4)	790 (26.2)	151 (29.8)	157 (29.9)	319 (20.8)
Risk of own death					
Moderate	1015 (18.2)	542 (18.0)	92 (18.1)	96 (18.3)	285 (18.6)
Strong	602 (10.8)	324 (10.8)	64 (12.6)	65 (12.4)	149 (9.7)
Extreme	799 (14.3)	444 (14.8)	87 (17.2)	84 (16.0)	184 (12.0)
Risk of others' death					
Moderate	1347 (24.2)	743 (24.7)	110 (21.7)	107 (20.4)	387 (25.3)
Strong	1154 (20.7)	598 (19.9)	119 (23.5)	115 (21.9)	322 (21.0)
Extreme	1327 (23.8)	723 (24.0)	136 (26.8)	151 (28.8)	317 (20.7)
Access to testing for COVID-19					
Moderate	1349 (24.2)	692 (23.0)	122 (24.1)	134 (25.5)	401 (26.2)
Strong	905 (16.2)	512 (17.0)	79 (15.6)	104 (19.8)	210 (13.7)
Extreme	1053 (18.9)	610 (20.3)	132 (26.0)	119 (22.7)	192 (12.5)
Access to medical care for COVID-19					
Moderate	1325 (23.8)	698 (23.2)	99 (19.5)	121 (23.0)	407 (26.6)
Strong	1047 (18.8)	562 (18.7)	107 (21.1)	102 (19.4)	276 (18.0)
Extreme	1222 (21.9)	689 (22.9)	141 (27.8)	140 (26.7)	252 (16.5)
Access to medical care for pre-existing conditions					
Moderate	1210 (21.7)	603 (20.0)	112 (22.1)	103 (19.6)	392 (25.6)
Strong	947 (17.0)	508 (16.9)	88 (17.4)	106 (20.2)	245 (16.0)
Extreme	1140 (20.5)	624 (20.7)	127 (25.0)	124 (23.6)	265 (17.3)

	Overall (N=5573)	US (N=3010)	NY (N=507)	LA (N=525)	AU (N=1531)
Concerns Related to COVID-19 and Mitigation Strategies					
Degree, if any, of concern about the following—No. (%)					
Social or physical isolation					
Moderate	1302 (23.4)	704 (23.4)	122 (24.1)	109 (20.8)	367 (24.0)
Strong	961 (17.2)	504 (16.7)	83 (16.4)	107 (20.4)	267 (17.4)
Extreme	974 (17.5)	526 (17.5)	108 (21.3)	101 (19.2)	239 (15.6)
Sense of purpose					
Moderate	1270 (22.8)	662 (22.0)	128 (25.2)	117 (22.3)	363 (23.7)
Strong	817 (14.7)	443 (14.7)	66 (13.0)	78 (14.9)	230 (15.0)
Extreme	690 (12.4)	352 (11.7)	73 (14.4)	82 (15.6)	183 (12.0)
Personal financial loss					
Moderate	1050 (18.8)	563 (18.7)	81 (16.0)	111 (21.1)	295 (19.3)
Strong	867 (15.6)	454 (15.1)	81 (16.0)	86 (16.4)	246 (16.1)
Extreme	1260 (22.6)	642 (21.3)	130 (25.6)	140 (26.7)	348 (22.7)
Possible economic recession					
Moderate	1157 (20.8)	620 (20.6)	103 (20.3)	88 (16.8)	346 (22.6)
Strong	1317 (23.6)	717 (23.8)	118 (23.3)	123 (23.4)	359 (23.4)
Extreme	1942 (34.8)	1004 (33.4)	182 (35.9)	223 (42.5)	533 (34.8)
Food and/or water insecurity					
Moderate	1314 (23.6)	726 (24.1)	106 (20.9)	99 (18.9)	383 (25.0)
Strong	764 (13.7)	404 (13.4)	83 (16.4)	73 (13.9)	204 (13.3)
Extreme	755 (13.5)	395 (13.1)	88 (17.4)	83 (15.8)	189 (12.3)
Open-endedness of the timeline of pandemic					
Moderate	1485 (26.6)	785 (26.1)	137 (27.0)	141 (26.9)	422 (27.6)
Strong	1249 (22.4)	659 (21.9)	113 (22.3)	111 (21.1)	366 (23.9)
Extreme	1290 (23.1)	706 (23.5)	133 (26.2)	146 (27.8)	305 (19.9)
Life Disruption due to COVID-19^d					
Spend considerable time consuming info—No. (%)					
No	3102 (55.7)	1669 (55.4)	294 (58.0)	287 (54.7)	852 (55.6)
Yes	2471 (44.3)	1341 (44.6)	213 (42.0)	238 (45.3)	679 (44.4)
Hours spent weekly—mean, sd	23.2 20.9	23.73 20.9	27.58 20.9	24.4 20.9	20.2 20.9
Sources of information					
Family	1022 (18.3) (41.4)	551 (18.3) (41.1)	82 (16.2) (38.5)	111 (21.1) (46.6)	278 (18.2) (40.9)
Workplace	637 (11.4) (25.8)	341 (11.3) (25.4)	50 (9.9) (23.5)	53 (10.1) (22.3)	193 (12.6) (28.4)
Healthcare providers	963 (17.3) (39.0)	514 (17.1) (38.3)	75 (14.8) (35.2)	104 (19.8) (43.7)	270 (17.6) (39.8)
Government officials	1619 (29.1) (65.5)	847 (28.1) (63.2)	137 (27.0) (64.3)	150 (28.6) (63.0)	485 (31.7) (71.4)
Media reports	1890 (33.9) (76.5)	1013 (33.7) (75.5)	167 (32.9) (78.4)	184 (35.0) (77.3)	526 (34.4) (77.5)
Social media	766 (13.7) (31.0)	378 (12.6) (28.2)	63 (12.4) (29.6)	78 (14.9) (32.8)	247 (16.1) (36.4)
Other	100 (1.8) (4.0)	58 (1.9) (4.3)	5 (1.0) (2.3)	13 (2.5) (5.5)	24 (1.6) (3.5)
Social Life—No. (%)					
Not at all affected	662 (11.9)	411 (13.7)	38 (7.5)	45 (8.6)	168 (11.0)
Disrupted	4195 (75.3)	2183 (72.5)	393 (77.5)	417 (79.4)	1202 (78.5)
Moderately	1879 (33.7) (44.8)	1050 (34.9) (48.1)	138 (27.2) (35.1)	156 (29.7) (37.4)	535 (34.9) (44.5)
Extremely	2316 (41.6) (55.2)	1133 (37.6) (51.9)	255 (50.3) (64.9)	261 (49.7) (62.6)	667 (43.6) (55.5)
Improved	437 (7.8)	255 (8.5)	49 (9.7)	41 (7.8)	92 (6.0)
Moderately	260 (4.7) (59.5)	151 (5.0) (59.2)	32 (6.3) (65.3)	21 (4.0) (51.2)	56 (3.7) (60.9)
Extremely	177 (3.2) (40.5)	104 (3.5) (40.8)	17 (3.4) (34.7)	20 (3.8) (48.8)	36 (2.4) (39.1)
Family Life—No. (%)					
Not at all affected	2227 (40.0)	1269 (42.2)	166 (32.7)	204 (38.9)	588 (38.4)
Disrupted	2284 (41.0)	1160 (38.5)	233 (46.0)	214 (40.8)	677 (44.2)
Moderately	1550 (27.8) (67.9)	791 (26.3) (68.2)	156 (30.8) (67.0)	142 (27.0) (66.4)	461 (30.1) (68.1)
Extremely	734 (13.2) (32.1)	369 (12.3) (31.8)	77 (15.2) (33.0)	72 (13.7) (33.6)	216 (14.1) (31.9)
Improved	746 (13.4)	411 (13.7)	72 (14.2)	82 (15.6)	181 (14.1)
Moderately	489 (8.8) (65.5)	263 (8.7) (64.0)	37 (7.3) (51.4)	57 (10.9) (69.5)	132 (8.6) (72.9)
Extremely	257 (4.6) (34.5)	148 (4.9) (36.0)	35 (6.9) (48.6)	25 (4.8) (30.5)	49 (3.2) (27.1)
Work/Studies—No. (%)					
Not at all affected	1167 (20.9)	677 (22.5)	71 (14.0)	114 (21.7)	305 (19.9)
Disrupted	2422 (43.5)	1254 (41.7)	239 (47.1)	243 (46.3)	686 (44.8)
Moderately	1287 (23.1) (53.1)	667 (22.2) (53.2)	121 (23.9) (50.6)	121 (23.0) (49.8)	378 (24.7) (55.1)
Extremely	1135 (20.4) (46.9)	587 (19.5) (46.8)	118 (23.3) (49.4)	122 (23.2) (50.2)	308 (20.1) (44.9)
Improved	405 (7.3)	225 (7.5)	48 (9.5)	41 (7.8)	91 (5.9)
Moderately	234 (4.2) (57.8)	127 (4.2) (56.4)	22 (4.3) (45.8)	25 (4.8) (61.0)	60 (3.9) (65.9)
Extremely	171 (3.1) (42.2)	98 (3.3) (43.6)	26 (5.1) (54.2)	16 (3.0) (39.0)	31 (2.0) (34.1)
Productivity—No. (%)					
Not at all affected	2127 (38.2)	1197 (39.8)	162 (32.0)	191 (36.4)	577 (37.7)
Disrupted	2317 (41.6)	1195 (39.7)	225 (44.4)	223 (42.5)	674 (44.0)
Moderately	1607 (28.8) (69.4)	838 (27.8) (70.1)	148 (29.2) (65.8)	146 (27.8) (65.5)	475 (31.0) (70.5)
Extremely	710 (12.7) (30.6)	357 (11.9) (29.9)	77 (15.2) (34.2)	77 (14.7) (34.5)	199 (13.0) (29.5)
Improved	799 (14.3)	446 (14.8)	84 (16.6)	85 (16.2)	184 (12.0)
Moderately	536 (9.6) (67.1)	286 (9.5) (64.1)	55 (10.8) (65.5)	62 (11.8) (72.9)	133 (8.7) (72.3)
Extremely	263 (4.7) (32.9)	160 (5.3) (35.9)	29 (5.7) (34.5)	23 (4.4) (27.1)	51 (3.3) (27.7)

^d For Life Disruption categories including Social Life, Family Life, Work/Studies, Productivity, Physical Activity, Sexual Activity, and Sleep Patterns, respondents had the option to select "does not apply." These answers are not included in the table and account for difference between the sum of "Not at all affected", "Disrupted", and "Improved" and 100%.

	Overall (N=5573)	US (N=3010)	NY (N=507)	LA (N=525)	AU (N=1531)
Life Disruption due to COVID-19					
Physical activity—No. (%)					
Not at all affected	1859 (33.4)	1084 (36.0)	122 (24.1)	159 (30.3)	494 (32.3)
Disrupted	2515 (45.1)	1245 (41.4)	258 (50.9)	265 (50.5)	747 (48.8)
Moderately	1496 (26.8) (59.5)	738 (24.5) (59.3)	147 (29.0) (57.0)	151 (28.8) (57.0)	460 (30.0) (61.6)
Extremely	1019 (18.3) (40.5)	507 (16.8) (40.7)	111 (21.9) (43.0)	114 (21.7) (43.0)	287 (18.7) (38.4)
Improved	827 (14.8)	484 (16.1)	83 (16.4)	75 (14.3)	185 (12.1)
Moderately	551 (9.9) (66.6)	328 (10.9) (67.8)	54 (10.7) (65.1)	49 (9.3) (65.3)	120 (7.8) (64.9)
Extremely	276 (5.0) (33.4)	156 (5.2) (32.2)	29 (5.7) (34.9)	26 (5.0) (34.7)	65 (4.2) (35.1)
Sexual activity—No. (%)					
Not at all affected	2546 (45.7)	1429 (47.5)	190 (37.5)	212 (40.4)	715 (46.7)
Disrupted	1313 (23.6)	668 (22.2)	134 (26.4)	148 (28.2)	363 (23.7)
Moderately	641 (11.5) (48.8)	340 (11.3) (50.9)	51 (10.1) (38.1)	64 (12.2) (43.2)	186 (12.1) (51.2)
Extremely	672 (12.1) (51.2)	328 (10.9) (49.1)	83 (16.4) (61.9)	84 (16.0) (56.8)	177 (11.6) (48.8)
Improved	559 (10.0)	329 (10.9)	70 (13.8)	51 (9.7)	109 (7.1)
Moderately	319 (5.7) (57.1)	183 (6.1) (55.6)	42 (8.3) (60.0)	28 (5.3) (54.9)	66 (4.3) (60.6)
Extremely	240 (4.3) (42.9)	146 (4.9) (44.4)	28 (5.5) (40.0)	23 (4.4) (45.1)	43 (2.8) (39.4)
Sleep patterns—No. (%)					
Not at all affected	2447 (43.9)	1377 (45.7)	187 (36.9)	201 (38.3)	682 (44.5)
Disrupted	2188 (39.3)	1128 (37.5)	204 (40.2)	240 (45.7)	616 (40.2)
Moderately	1563 (28.0) (71.4)	799 (26.5) (70.8)	130 (25.6) (63.7)	167 (31.8) (69.6)	467 (30.5) (75.8)
Extremely	625 (11.2) (28.6)	329 (10.9) (29.2)	74 (14.6) (36.3)	73 (13.9) (30.4)	149 (9.7) (24.2)
Improved	666 (12.0)	354 (11.8)	85 (16.8)	62 (11.8)	165 (10.8)
Moderately	476 (8.5) (71.5)	254 (8.4) (71.8)	66 (13.0) (77.6)	41 (7.8) (66.1)	115 (7.5) (69.7)
Extremely	190 (3.4) (28.5)	100 (3.3) (28.2)	19 (3.7) (22.4)	21 (4.0) (33.9)	50 (3.3) (30.3)
Specific Changes to Daily Activity Comparing Between October and December 2019 with Current Life					
Interactions with others ^e —No. (%)					
Interactions between October and December 2019 were...					
Almost all virtual	330 (5.9)	188 (6.2)	33 (6.5)	32 (6.1)	77 (5.0)
More virtual than face to face	484 (8.7)	271 (9.0)	50 (9.9)	47 (9.0)	116 (7.6)
About equally virtual and face to face	1588 (28.5)	903 (30.0)	122 (24.1)	139 (26.5)	424 (27.7)
More face to face than virtual	1605 (28.8)	838 (27.8)	135 (26.6)	174 (33.1)	458 (29.9)
Almost all face to face	1232 (22.1)	624 (20.7)	133 (26.2)	110 (21.0)	365 (23.8)
Interactions in the past week were...					
Almost all virtual	2137 (38.3)	1119 (37.2)	221 (43.6)	242 (46.1)	555 (36.3)
More virtual than face to face	1547 (27.8)	821 (27.3)	141 (27.8)	141 (26.9)	444 (29.0)
About equally virtual and face to face	949 (17.0)	556 (18.5)	62 (12.2)	67 (12.8)	264 (17.2)
More face to face than virtual	248 (4.5)	144 (4.8)	18 (3.6)	19 (3.6)	67 (4.4)
Almost all face to face	231 (4.1)	128 (4.3)	18 (3.6)	18 (3.4)	67 (4.4)
Work [of respondents employed between October and December 2019, N=3328—No. (%)]					
Days of paid work per week					
Not changed—No. (%)	1757 (31.5) (52.8)	953 (31.7) (53.4)	184 (36.3) (54.6)	163 (31.0) (49.8)	457 (29.8) (52.0)
Decreased—No. (%)	1329 (23.8) (39.9)	685 (22.8) (38.4)	134 (26.4) (39.8)	146 (27.8) (44.6)	364 (23.8) (41.4)
Increased—No. (%)	242 (4.3) (7.3)	147 (4.9) (8.2)	19 (3.7) (5.6)	18 (3.4) (5.5)	58 (3.8) (6.6)
Between Oct and Dec 2019—mean (sd)	4.7 (1.3)	4.8 (1.2)	4.8 (1.3)	4.8 (1.2)	4.4 (1.4)
Currently—mean (sd)	3.5 (2.2)	3.7 (2.2)	3.5 (2.3)	3.3 (2.3)	3.2 (2.2)
Hours of paid work per week					
Not changed—No. (%)	950 (17.0) (28.5)	503 (16.7) (28.2)	88 (17.4) (26.1)	85 (16.2) (26.0)	274 (17.9) (31.2)
Decreased—No. (%)	1735 (31.1) (52.1)	909 (30.2) (50.9)	180 (35.5) (53.4)	182 (34.7) (55.7)	464 (30.3) (52.8)
Increased—No. (%)	643 (11.5) (19.3)	373 (12.4) (20.9)	69 (13.6) (20.5)	60 (11.4) (18.3)	141 (9.2) (16.0)
Between Oct and Dec 2019—mean (sd)	41.5 (18.8)	43.6 (19.2)	42.6 (18.7)	43.2 (20.5)	36.4 (17.5)
Currently—mean (sd)	31.4 (24.2)	33.6 (25.2)	32.1 (24.6)	31.3 (27.7)	26.8 (21.0)
Commute—No. (%)					
Not changed					
Decreased daily commute	1108 (19.9)	546 (18.1)	134 (26.4)	103 (19.6)	325 (21.2)
by less than 1 hour	695 (12.5) (62.7)	355 (11.8) (65.0)	79 (15.6) (59.0)	67 (12.8) (65.0)	194 (12.7) (59.7)
by 1-3 hours	203 (3.6) (18.3)	87 (2.9) (15.9)	30 (5.9) (22.4)	23 (4.4) (22.3)	63 (4.1) (19.4)
by 3-5 hours	29 (0.5) (2.6)	17 (0.6) (3.1)	4 (0.8) (3.0)	0 (0.0) (0.0)	8 (0.5) (2.5)
by 5+ hours	181 (3.2) (16.3)	87 (2.9) (15.9)	21 (4.1) (15.7)	13 (2.5) (12.6)	60 (3.9) (18.5)
Increased daily commute	116 (2.1)	49 (1.6)	15 (3.0)	16 (3.0)	36 (2.4)
by less than 1 hour	73 (1.3) (62.9)	31 (1.0) (63.3)	10 (2.0) (66.7)	10 (1.9) (62.5)	22 (1.4) (61.1)
by 1-3 hours	23 (0.4) (19.8)	6 (0.2) (12.2)	3 (0.6) (20.0)	4 (0.8) (25.0)	10 (0.7) (27.8)
by 3-5 hours	10 (0.2) (8.6)	6 (0.2) (12.2)	1 (0.2) (6.7)	2 (0.4) (12.5)	1 (0.1) (2.8)
by 5+ hours	10 (0.2) (8.6)	6 (0.2) (12.2)	1 (0.2) (6.7)	0 (0.0) (0.0)	3 (0.2) (8.3)
Weekly exercise frequency					
Not changed—No. (%)	2649 (47.5)	1479 (49.1)	230 (45.4)	221 (42.1)	719 (47.0)
Decreased—No. (%)	1999 (35.9)	994 (33.0)	198 (39.1)	216 (41.1)	591 (38.6)
Increased—No. (%)	925 (16.6)	537 (17.8)	79 (15.6)	88 (16.8)	221 (14.4)
Days between Oct and Dec 2019—mean	3.5 (2.1)	3.5 (2.1)	3.4 (2.0)	3.5 (2.0)	3.4 (2.2)
Days currently—mean (sd)	3.0 (2.3)	3.1 (2.3)	2.7 (2.2)	3.0 (2.3)	2.8 (2.3)

^e For Interactions with others, respondents had the option to select "does not apply." These answers are not included in the table and account for difference between the other summed categories and 100%.

	Overall (N=5573)	US (N=3010)	NY (N=507)	LA (N=525)	AU (N=1531)
Specific Changes to Dailiy Activity Comparing Between October and December 2019 with Current Life					
Weight—No. (%)					
Not changed	4841 (86.9)	2604 (86.5)	434 (85.6)	444 (84.6)	1359 (88.8)
Increased	531 (9.5)	293 (9.7) (72.2)	49 (9.7)	61 (11.6) (75.3)	128 (8.4)
Not at all concerned	122 (2.2) (23.0)	77 (2.6) (26.3)	9 (1.8) (18.4)	11 (2.1) (18.0)	25 (1.6) (19.5)
Somewhat concerned	310 (5.6) (58.4)	163 (5.4) (55.6)	28 (5.5) (57.1)	41 (7.8) (67.2)	78 (5.1) (60.9)
Extremely concerned	99 (1.8) (18.6)	53 (1.8) (18.1)	12 (2.4) (24.5)	9 (1.7) (14.8)	25 (1.6) (19.5)
Decreased	201 (3.6)	113 (3.8) (27.8)	24 (4.7)	20 (3.8) (24.7)	44 (2.9)
Not at all concerned	98 (1.8) (48.8)	64 (2.1) (56.6)	4 (0.8) (16.7)	9 (1.7) (45.0)	21 (1.4) (47.7)
Somewhat concerned	62 (1.1) (30.8)	32 (1.1) (28.3)	5 (1.0) (20.8)	7 (1.3) (35.0)	18 (1.2) (40.9)
Extremely concerned	41 (0.7) (20.4)	17 (0.6) (15.0)	15 (3.0) (62.5)	4 (0.8) (20.0)	5 (0.3) (11.4)
Daylight exposure—No. (%)					
Not changed	1982 (35.6)	1188 (39.5)	120 (23.7)	142 (27.0)	532 (34.7)
Increased	881 (15.8)	502 (16.7)	61 (12.0)	92 (17.5)	226 (14.8)
by less than 1 hour	243 (4.4) (27.6)	156 (5.2) (31.1)	10 (2.0) (16.4)	24 (4.6) (26.1)	53 (3.5) (23.5)
by 1 to 3 hours	367 (6.6) (41.7)	222 (7.4) (44.2)	23 (4.5) (37.7)	34 (6.5) (37.0)	88 (5.7) (38.9)
by more than 3 hours	271 (4.9) (30.8)	124 (4.1) (24.7)	28 (5.5) (45.9)	34 (6.5) (37.0)	85 (5.6) (37.6)
Decreased	2710 (48.6)	1320 (43.9)	326 (64.3)	291 (55.4)	773 (50.5)
by less than 1 hour	431 (7.7) (15.9)	231 (7.7) (17.5)	44 (8.7) (13.5)	46 (8.8) (15.8)	110 (7.2) (14.2)
by 1 to 3 hours	979 (17.6) (36.1)	492 (16.3) (37.3)	93 (18.3) (28.5)	107 (20.4) (36.8)	287 (18.7) (37.1)
by more than 3 hours	1300 (23.3) (48.0)	597 (19.8) (45.2)	189 (37.3) (58.0)	138 (26.3) (47.4)	376 (24.6) (48.6)
Screen time—No. (%)					
Not changed	2689 (48.3)	1543 (51.3)	212 (41.8)	231 (44.0)	703 (45.9)
Increased	2145 (38.5)	1062 (35.3)	210 (41.4)	226 (43.0)	647 (42.3)
by less than 1 hour	359 (6.4) (16.7)	184 (6.1) (17.3)	34 (6.7) (16.2)	42 (8.0) (18.6)	99 (6.5) (15.3)
by 1 to 3 hours	799 (14.3) (37.2)	408 (13.6) (38.4)	70 (13.8) (33.3)	73 (13.9) (32.3)	248 (16.2) (38.3)
by more than 3 hours	987 (17.7) (46.0)	470 (15.6) (44.3)	106 (20.9) (50.5)	111 (21.1) (49.1)	300 (19.6) (46.4)
Decreased	739 (13.3)	405 (13.5)	85 (16.8)	68 (13.0)	181 (11.8)
by less than 1 hour	223 (4.0) (30.2)	125 (4.2) (30.9)	27 (5.3) (31.8)	19 (3.6) (27.9)	52 (3.4) (28.7)
by 1 to 3 hours	258 (4.6) (34.9)	136 (4.5) (33.6)	29 (5.7) (34.1)	23 (4.4) (33.8)	70 (4.6) (38.7)
by more than 3 hours	258 (4.6) (34.9)	144 (4.8) (35.6)	29 (5.7) (34.1)	26 (5.0) (38.2)	59 (3.9) (32.6)
Mental Health					
Respondents answers to the following prompts about the past two weeks—No. (%)					
Feeling nervous, depressed, or anxious					
Not at all	2454 (44.0)	1349 (44.8)	208 (41.0)	217 (41.3)	680 (44.4)
Several days	1912 (34.3)	1007 (33.5)	177 (34.9)	191 (36.4)	537 (35.1)
More than half the days	636 (11.4)	318 (10.6)	72 (14.2)	69 (13.1)	177 (11.6)
Nearly everyday	571 (10.2)	336 (11.2)	50 (9.9)	48 (9.1)	137 (8.9)
Not being able to stop or control worrying					
Not at all	3062 (54.9)	1687 (56.0)	283 (55.8)	282 (53.7)	810 (52.9)
Several days	1494 (26.8)	762 (25.3)	124 (24.5)	152 (29.0)	456 (29.8)
More than half the days	552 (9.9)	289 (9.6)	61 (12.0)	55 (10.5)	147 (9.6)
Nearly everyday	465 (8.3)	272 (9.0)	39 (7.7)	36 (6.9)	118 (7.7)
Little interest or pleasure in doing things					
Not at all	3117 (55.9)	1773 (58.9)	270 (53.3)	274 (52.2)	800 (52.3)
Several days	1449 (26.0)	706 (23.5)	151 (29.8)	154 (29.3)	438 (28.6)
More than half the days	565 (10.1)	301 (10.0)	52 (10.3)	51 (9.7)	161 (10.5)
Nearly everyday	442 (7.9)	230 (7.6)	34 (6.7)	46 (8.8)	132 (8.6)
Feeling down, depressed, or hopeless					
Not at all	3120 (56.0)	1761 (58.5)	269 (53.1)	291 (55.4)	799 (52.2)
Several days	1477 (26.5)	737 (24.5)	145 (28.6)	146 (27.8)	449 (29.3)
More than half the days	541 (9.7)	273 (9.1)	58 (11.4)	49 (9.3)	161 (10.5)
Nearly everyday	435 (7.8)	239 (7.9)	35 (6.9)	39 (7.4)	122 (8.0)

Table 1. Survey responses are reported using descriptive statistics as indicated, including number of respondents (No.), percentage of respondents within a region (%), mean, and standard deviation (sd). For cases in which subgroups are stratified, the percentage of the total sample is reported first, and then percentage of the subgroup is reported in the second parentheses. For cases in which subgroups are not stratified, or

where means and standard deviations are reported, the to the right is left blank. For the “Concerns Related to COVID-19 and Mitigation Strategies” section, only respondents rating moderate to extreme concern are reported (respondents reporting no or slight concern, or that the concern does not apply, are not shown). Country-level cumulative cases and deaths for US and AU were retrieved from World Health Organization COVID-19 Situational Reports.^{1,28-29} City-level cumulative cases and deaths for NY and LA were retrieved from The New York Times Coronavirus (Covid-19) Data in the United States project, based on reports from state and local health agencies.²

Table 2. Self-Reported Respondent Characteristics

Characteristic	Overall (N=5573)	US (N=3010)	NY (N=507)	LA (N=525)	(N=1531)
Age (years)					
Mean (SD)	47.1 (17.3)	47.4 (16.9)	46.7 (18.0)	45.5 (17.0)	45.6 (17.3)
Median	47	48	45	45	44.5
Range	18-89	18-89	18-86	18-87	18-89
Gender—No. (%)					
Female	3039 (54.5)	1683 (55.9)	239 (47.1)	275 (52.4)	842 (55.0)
Male	2530 (45.4)	1325 (44.0)	268 (52.9)	250 (47.6)	687 (44.9)
Other	4 (0.1)	2 (0.1)	0 (0.0)	0 (0.0)	2 (0.1)
Race^a (All US, N=4042)—No. (%)					
White	3196 (79.1)	2423 (80.5)	373 (73.6)	400 (76.2)	
Black or African American	428 (10.6)	313 (10.4)	63 (12.4)	52 (9.9)	
Asian	256 (6.3)	192 (6.4)	32 (6.3)	32 (6.1)	
American Indian or Alaskan Native	80 (2.0)	60 (2.0)	9 (1.8)	11 (2.1)	
Native Hawaiian or Pacific Islander	22 (0.5)	17 (0.6)	3 (0.6)	2 (0.4)	
Other	182 (4.5)	104 (3.5)	38 (7.5)	40 (7.6)	
Ethnicity (All US, N=4042)—No. (%)					
Hispanic or Latino	424 (10.5)	265 (8.8)	69 (13.6)	90 (17.1)	
Not Hispanic or Latino	3618 (89.5)	2745 (91.2)	438 (86.4)	435 (82.9)	
Ancestry^b (AU, N=1531)—No. (%)					
Australian					556 (36.3)
English					501 (32.7)
Other European (Irish, Scottish, German, Italian, Greek, Dutch)					346 (22.6)
Scottish					95 (6.2)
Chinese					90 (5.9)
Indian					45 (2.9)
Indigenous—Aboriginal Australians and Torres Strait Islanders					16 (1.0)
Other					455 (29.8)
Highest degree or level of education completed—No. (%)					
Less than high school	107 (1.9)	61 (2.0)	4 (0.8)	5 (1.0)	37 (2.4)
High school or equivalent	1257 (22.6)	524 (17.4)	81 (16.0)	61 (11.6)	591 (38.6)
Some college	1444 (25.9)	910 (30.2)	121 (23.9)	157 (29.9)	256 (16.7)
Bachelor's degree (4-year) or equivalent	1806 (32.4)	927 (30.8)	159 (31.4)	212 (40.4)	508 (33.2)
Doctoral or professional degree	917 (16.5)	567 (18.8)	137 (27.0)	88 (16.8)	125 (8.2)
Prefer not to say	42 (0.8)	21 (0.7)	5 (1.0)	2 (0.4)	14 (0.9)
^a For the US sample, respondents had the option to select more than one racial affiliation.					
^b For the AU sample, respondents had the option to select up to two ancestral affiliations. The 'Other' category includes Filipino, Vietnamese, Lebanese, Hmong, Kurdish, Maori, and Australian South Sea Islander.					

Characteristic	Overall (N=5573)	US (N=3010)	NY (N=507)	LA (N=525)	AU (N=1531)
Marital status—No. (%)					
Married	2724 (48.9)	1567 (52.1)	231 (45.6)	226 (43.0)	700 (45.7)
Living with partner	533 (9.6)	241 (8.0)	43 (8.5)	51 (9.7)	198 (12.9)
Separated	92 (1.7)	32 (1.1)	7 (1.4)	2 (0.4)	51 (3.3)
Divorced	490 (8.8)	291 (9.7)	40 (7.9)	46 (8.8)	113 (7.4)
Widowed	178 (3.2)	109 (3.6)	12 (2.4)	21 (4.0)	36 (2.4)
Never married	1490 (26.7)	739 (24.6)	165 (32.5)	169 (32.2)	417 (27.2)
Prefer not to say	66 (1.2)	31 (1.0)	9 (1.8)	10 (1.9)	16 (1.0)
2019 household income (USD)—No. (%)					
Less than \$24,999	940 (16.9)	454 (15.1)	57 (11.2)	67 (12.8)	362 (23.6)
\$25,000 to \$49,999	1296 (23.3)	641 (21.3)	88 (17.4)	88 (16.8)	479 (31.3)
\$50,000 to \$99,999	1723 (30.9)	989 (32.9)	139 (27.4)	164 (31.2)	431 (28.2)
\$100,000 to \$199,999	1054 (18.9)	657 (21.8)	151 (29.8)	134 (25.5)	112 (7.3)
More than \$200,000	229 (4.1)	132 (4.4)	41 (8.1)	42 (8.0)	14 (0.9)
Prefer not to say	331 (5.9)	137 (4.6)	31 (6.1)	30 (5.7)	133 (8.7)
2019 employment status—No. (%)					
Employed full-time	2245 (40.3)	1284 (42.7)	246 (48.5)	217 (41.3)	498 (32.5)
Employed part-time	760 (13.6)	338 (11.2)	63 (12.4)	61 (11.6)	298 (19.5)
Self-employed	361 (6.5)	189 (6.3)	30 (5.9)	52 (9.9)	90 (5.9)
Student	337 (6.0)	147 (4.9)	30 (5.9)	36 (6.9)	124 (8.1)
Retired	1268 (22.8)	734 (24.4)	101 (19.9)	110 (21.0)	323 (21.1)
Unemployed	714 (12.8)	384 (12.8)	45 (8.9)	55 (10.5)	230 (15.0)
Political ideology—No. (%)					
Very liberal	701 (12.6)	410 (13.6)	97 (19.1)	94 (17.9)	100 (6.5)
Slightly liberal	1121 (20.1)	586 (19.5)	107 (21.1)	129 (24.6)	299 (19.5)
Neither liberal nor conservative	1465 (26.3)	727 (24.2)	122 (24.1)	126 (24.0)	490 (32.0)
Slightly conservative	1097 (19.7)	621 (20.6)	80 (15.8)	84 (16.0)	312 (20.4)
Very conservative	701 (12.6)	484 (16.1)	60 (11.8)	58 (11.0)	99 (6.5)
Apolitical and/or prefer not to say	488 (8.8)	182 (6.0)	41 (8.1)	34 (6.5)	231 (15.1)

Table 2. Self-reported characteristics overall and in quota samples collected in the US, NY, LA, and AU. For age, mean (standard deviation), median, and range are shown per sample. For all other characteristics, the number and percentage of respondents are reported by cohort. Race and ethnicity (US, NY, LA) or ancestry (AU) were reported in based on questions culturally adapted to match the characteristic data collected in the 2010 United States and 2016 Australian Census, respectively.